STOCK TITAN
  1. Home
  2. News
  3. BLRX

Bioline Rx Ltd - BLRX STOCK NEWS

Welcome to our dedicated news page for Bioline Rx (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Bioline Rx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioline Rx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioline Rx's position in the market.

News
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
Rhea-AI Summary
BioLineRx announces a poster presentation on apheresis center efficiency and CXCR4 antagonists, including APHEXDA (motixafortide), in patients with multiple myeloma at the ASFA 2024 Annual Meeting. The presentation focuses on the number of apheresis days needed to collect stem cells for ASCT, comparing different mobilization regimens. The model analyzed data from Phase 3 studies and supported the FDA approval of APHEXDA. The research aims to address operational challenges in apheresis centers and improve patient experiences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
Rhea-AI Summary
BioLineRx secures $20 million in non-dilutive debt financing from BlackRock to advance APHEXDA® in stem cell mobilization, sickle cell disease, and motixafortide metastatic pancreatic cancer program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.99%
Tags
none
-
News
BioLineRx Announces $6 Million Registered Direct Offering
Rhea-AI Summary
BioLineRx announces a registered direct offering of 7,500,000 American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs at $0.80 per ADS, aiming to raise funds for its life-changing therapies in oncology and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.21%
Tags
offering
News
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Rhea-AI Summary
BioLineRx (BLRX) reported significant commercial progress for APHEXDA®, securing payer coverage for ~95% of covered lives in the U.S. They announced the first patient dosed in a Phase 2b clinical trial for motixafortide in pancreatic cancer, along with continued support for partner Gloria Biosciences in China. Financially, the company had total revenues of $4.8 million in 2023, with a net loss of $60.6 million. The company's vision of bringing innovative therapies to market and their progress in various clinical programs demonstrate a promising future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.77%
Tags
earnings
-
News
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
Rhea-AI Summary
BioLineRx to Release Audited Financial Results for 2023 on March 26, 2024, Hosting Conference Call with CEO Philip Serlin at 08:30 a.m. EDT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences earnings
-
News
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
Rhea-AI Summary
BioLineRx receives a Notice of Allowance from the USPTO for a patent covering the manufacturing process of motixafortide, extending its IP portfolio until December 2041. The company has secured Orphan Drug and New Chemical Entity market exclusivity for motixafortide, enhancing its commercial potential in oncology and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
News
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
Rhea-AI Summary
BioLineRx Ltd. announced the initiation of the CheMo4METPANC Phase 2 trial in collaboration with Columbia University, evaluating motixafortide with a PD-1 inhibitor and standard chemotherapies for pancreatic cancer. Positive pilot phase data showed a 91% disease control rate, with 64% experiencing partial responses. Motixafortide, the company's lead candidate, was FDA-approved for stem cell mobilization in multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
clinical trial
-
News
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
BioLineRx Ltd. announces presentation of new post-hoc subgroup analyses and pharmacodynamic data on APHEXDA for CD34+ hematopoietic stem cell mobilization in multiple myeloma patients at the 2024 Tandem Meetings. The Phase 3 GENESIS trial results show positive pharmacokinetic and pharmacodynamic data, highlighting the efficacy of motixafortide + G-CSF over placebo + G-CSF mobilization for all patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.61%
Tags
none
-
News
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
Rhea-AI Summary
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) announced the dosing of the first patient in a Phase 1 clinical trial evaluating motixafortide for CD34+ hematopoietic stem cell mobilization for gene therapies in sickle cell disease. The trial aims to identify more efficient mobilization regimens for patients with sickle cell disease choosing gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
clinical trial
News
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Rhea-AI Summary
BioLineRx Ltd. (NASDAQ: BLRX) received FDA approval for APHEXDA® in combination with Filgrastim for stem cell mobilization in multiple myeloma patients. They also closed an exclusive license agreement for motixafortide in the Asia region, alongside strategic equity investment. They presented encouraging data at AACR from a pilot phase of a randomized phase 2 combination trial with motixafortide in first-line PDAC. Additionally, they began enrollment for a phase 1 trial evaluating motixafortide for stem cell mobilization in sickle cell disease patients seeking gene therapy. The company will host a conference call today, November 20, at 10:00 a.m. EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
earnings
Stock BLRX logo
Bioline Rx Ltd

Nasdaq:BLRX

BLRX Rankings

#4765 Ranked by Market Cap
#355 Ranked by Stock Gains
N/A Ranked by Dividends

BLRX Stock Data

54.26M
989.89M
8.54%
1.44%
0.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
2 Hamaayan Street

About BLRX

biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'​in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain content posted by a third party or links to third party websites (the “content” or “third party content”). this content is provided solely for general informational purposes as a convenience to you and not as an endorsement by the company of the content. it does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. the company is not responsible for this content and does not make any representations as to the subject matter, accuracy, completeness or timeliness or the content. if you decide to access linked third party websites, you do so at your own risk. there is no warranty of any kind, express or implied, regarding the content, including without limitation any warranty of m